title: [Plasmapheresis combined with pharmacology in the treatment of lupus nephritis: a new therapeutic protocol].
abstract: Systemic Lupus Erythematosus (SLE) is a pathology of unknown cause, characterized by tissue and cellular damage, secondary to production of autoantibodies and to deposition of immunocomplexes. Lupus nephritis is one of the most common complications of SLE. Our purpose is to propose a therapeutic protocol for patients suffering from Lupus nephritis. This consists of Plasmapheresis associated with pharmacological therapy so that dosage of immunosuppressors can be reduced and consequently also the side effects of the pharmacological therapy.
authors.affiliation: Istituto di I Clinica Medica, Ambulatorio di Plasmaferesi e Dialisi, Policlinico Umberto I Roma, Università degli Studi di Roma La Sapienza, Italia. gerusso@uniroma1.it
authors.forename: G E
authors.initials: GE
authors.lastname: Russo
authors.forename: M
authors.initials: M
authors.lastname: Bonello
authors.forename: E
authors.initials: E
authors.lastname: Vitaliano
authors.forename: M
authors.initials: M
authors.lastname: Bosco
authors.forename: L
authors.initials: L
authors.lastname: Maresca
authors.forename: A
authors.initials: A
authors.lastname: De Paola
authors.forename: M
authors.initials: M
authors.lastname: Tedaldi
authors.forename: M F
authors.initials: MF
authors.lastname: Bisciglia
authors.forename: B
authors.initials: B
authors.lastname: Bauco
mesh_terms: D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000628:therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D010956:Plasmapheresis; D011507:Proteinuria / Q000628:therapy
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003404:Creatinine; D008775:Methylprednisolone